Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)
Close on Nov 13, 2026Market cap $7.92BP/E –Yield –
Rhythm Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Rhythm Pharmaceuticals's price to sales ratio was 32.2× on Nov 11, 2026, against 41.7× a year earlier. Over the last 5 years it ranged from 23.7× to 183.7×, with a median of 33.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 32.2× | −8.8 |
| 2025 | Dec 31, 2025 | 40.9× | +10.4 |
| 2024 | Dec 31, 2024 | 30.6× | −13.3 |
| 2023 | Dec 29, 2023 | 43.8× | −53.6 |
| 2022 | Dec 30, 2022 | 97.4× | – |
See a number that looks wrong?